Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Dublin, Oct. 20, 2016 -- Research and Markets has announced the addition of the "The Overview of Japanese Generic Drug Market" report to their offering.
This report talks about the overview of Japanese generic drug market.
The readers will understand overall climate surrounding generic market in Japan. The report covers related regulations, generics's share in Japan, market size, primary makers, market trend, and updated situation about biosimilars and authorized generics.
The share of generics in the prescription drugs market has been dramatically increasing in terms of both volume and value. The recent volume share was 60.1% in the 2nd quarter in 2016. This increase has been particularly pronounced since 2007 due to government measures devised to increase the use of generics.
Key Topics Covered:
1. Summary
2. Definition of Generic Drugs
3. Laws and Regulations Pertaining to Generics
4. NHI Drug Price
5. Share of Generics in Prescription Drugs Market
6. Market Size
7. Principal Industry Association
8. Sales of Major Japanese Generic Companies
9. Primary Generic Manufacturers
10. Overview of Leading Japanese Generics Companies
11. Current Market Environment Conditions
12. Considerations by Company Type
13. Government Measures to Promote the Use of Generics
14. Biosimilars
15. Authorized Generics
16. Future Outlook
Companies Mentioned
- Actavis
- Boehringer Ingelheim
- Daiichi Sankyo
- Hospira
- Lupin
- Meiji
- Mochida
- Mylan
- Nichi-Iko
- Nippon Chemiphar
- Nippon Kayaku,Kissei
- Ohara
- Sandoz
- Sanwa
- Sawai
- Teva
- Towa
- Zydus
For more information about this report visit http://www.researchandmarkets.com/research/fpctz5/the_overview_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Generic Drugs
